# US 2023/0054634 A1 · Compositions and methods for treating glioma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054634 A1
- Document ID: US20230054634A1
- Status: Published application
- Kind: A1
- Application number: 17/298,285
- Filed: 2019-11-27
- Published: 2023-02-23
- Earliest claimed: 2018-11-28
- Assignees: Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk
- Applicants: Glia Sp. Z O.O.
- Inventors: Bozena KAMINSKA-KACZMAREK; Aleksandra ELLERT-MIKLASZEWSKA; Katarzyna POLESZAK; Maria PASIERBINSKA; Pawel WISNIEWSKI
- Web page: https://patentgrep.com/patent/US20230054634A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to isolated peptides, compositions comprising same and methods of use thereof for treating tumors infiltrated with macrophages, such as glioblastomas.

## Claims

### Claim 1

An isolated artificial peptide for inhibiting GM-CSF activity, said peptide comprising an amino acid sequence selected from the group consisting of:
an amino acid sequence set forth in SEQ ID NO: 1 or variants thereof, SEQ ID NO: 23, SEQ ID NO: 24, wherein said peptide is of 10-20 amino acids, and wherein each of the variants of SEQ ID NO: 1 is selected from SEQ ID NO: 1 with substitution of amino acids in any one or more of positions 2, 3, 5, 6, 9 and 11-13 with alanine or lysine and/or addition of lysine at the N-terminus of SEQ ID NO: 1.

### Claim 2 (depends on 1)

The isolated artificial peptide of claim 1, wherein said peptide comprises SEQ ID NO: 1 or the variants thereof.

### Claim 3 (depends on 2)

The isolated artificial peptide of claim 2, wherein said peptide is consisting of SEQ ID NO: 1 or the variants thereof.

### Claim 4 (depends on 1)

The isolated artificial peptide of claim 1, wherein said peptide comprises an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NOs: 17-19, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 32 and SEQ ID NO: 35.

### Claim 5 (depends on 2)

The isolated artificial peptide of claim 2, comprising an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 32 and SEQ ID NO: 35.

### Claim 6 (depends on 5)

The isolated artificial peptide of claim 5, comprising an amino acid sequence selected from: SEQ ID NO: 1, SEQ ID NO: 8 and SEQ ID NOs: 17-19.

### Claim 7 (depends on 4)

The isolated artificial peptide of claim 4, consisting of an amino acid sequence selected from: SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NOs: 17-19, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 32 and SEQ ID NO: 35.

### Claim 8 (depends on 5)

The isolated artificial peptide of claim 5, consisting of an amino acid sequence selected from: SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NOs: 17-19, SEQ ID NO: 32 and SEQ ID NO: 35.

### Claim 9 (depends on 6)

The isolated artificial peptide of claim 6, consisting of an amino acid sequence selected from: SEQ ID NO: 1, SEQ ID NO: 8 and SEQ ID NOs: 17-19.

### Claim 10 (depends on 1)

The isolated artificial peptide of claim 1 wherein said peptide consists of the sequence set forth in SEQ ID NO: 23, or an analog or derivative thereof.

### Claim 11 (depends on 1)

The isolated artificial peptide of claim 1 wherein said peptide consists of the sequence set forth in SEQ ID NO: 24, or an analog or derivative thereof.

### Claim 12 (depends on 1)

The isolated artificial peptide of claim 1, wherein said peptide is fused to a peptide assisting transport through the blood brain barrier (BBB).

### Claim 13 (depends on 1)

The isolated peptide of claim 1, wherein said peptide is a cyclic peptide.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the isolated artificial peptide of claim 1 and a pharmaceutical acceptable carrier.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14 for inhibiting migration of tumor cells.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15 wherein the tumor is glioma.

### Claim 17 (depends on 14)

The pharmaceutical composition of claim 14 for the treatment of glioma.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, wherein said glioma is selected from the group consisting of: ependymoma, astrocytoma, oligodendroglioma, glioblastoma, or a mixed glioma.

### Claim 19

A method of treating glioma comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a peptide capable of inhibiting GM-CSF activity, wherein said peptide comprises a sequence selected from the group consisting of: an amino acid sequence set forth in SEQ ID NO: 1 or variants thereof, an amino acid sequence set forth in SEQ ID NO: 23, and an amino acid sequence set forth in SEQ ID NO: 24, wherein said peptide is of 10-20 amino acids, and wherein each of the variants of SEQ ID NO: 1 is selected from SEQ ID NO: 1 with substitution of amino acids in any one or more of positions 2, 3, 5, 6, 9 and 11-13 with alanine or lysine and/or addition of lysine at the N-terminus of SEQ ID NO: 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the peptide comprises the sequence set forth in SEQ ID NO: 1, or the variants thereof.

### Claim 21 (depends on 19)

The method of claim 19, wherein treating glioma comprises inhibiting migration of tumor cells from the tumor to the cerebrospinal fluid.